Latest Developments in Fibroid Research


Introduction: The Progressive Field of Uterine Fibroids Research 

Uterine fibroids are non-cancerous growths in the uterus that significantly impact women’s health worldwide. Despite being benign, they can lead to severe symptoms (1) such as heavy menstrual bleeding, pelvic pain, and fertility issues. That said, recent years have seen notable advancements in fibroid research, offering new hope and improved treatments for those affected.  

This blog aims to explore these developments, shedding light on the genetic, environmental, and medical breakthroughs that are shaping the future of fibroid treatment. 

The Global and Societal Impact of Uterine Fibroids 

Uterine fibroids pose a significant global health burden, affecting millions of women and impacting their quality of life. Tailoring healthcare approaches to different populations and raising awareness about fibroids are essential steps in addressing this widespread issue effectively. 

Decoding the Pathogenesis of Uterine Fibroids 

Genetic Insights: The Role of MED12 Gene Mutation 

Recent studies (2) have identified a link between mutations in the MED12 gene (3) and the development of fibroids. This gene, (4) crucial for regulating cell growth, can lead to abnormal growth in the uterine muscles when mutated.  

Understanding better this genetic factor will allow a significant step towards developing targeted therapies. It has the potential to open the door for personalized medicine approaches, where treatments could be tailored based on a woman’s genetic makeup. 

Environmental and Hormonal Risk Factors 

The interaction between environmental factors and hormonal imbalances has also been a recent research focus, with lLifestyle factors, (5) diet, and exposure to certain chemicals having been shown to be implicated in fibroid development.  

Additionally, hormones like estrogen and progesterone are known to be crucial in fibroid growth. This comprehensive understanding of the potential causes allows for a more holistic approach to prevention and treatment, focusing on lifestyle modifications alongside medical interventions. 

Innovations in Diagnosing Fibroids 

Advanced Imaging Techniques for Better Detection 

Advancements in imaging technologies (6) such as high-resolution ultrasound and MRI (7) have significantly improved the detection and mapping of fibroids. These methods provide detailed images, allowing for accurate diagnosis and helping in planning more effective treatment strategies. 

Predictive Diagnostic Aglorithms 

The development of predictive algorithms has been a game-changer in fibroid management. Using these algorithms and advanced imaging, the growth trajectory of fibroids and the potential need for surgical interventions can be predicted. This proactive approach aids in early intervention, potentially reducing the need for more invasive treatments. 

New Horizons in Fibroid Treatment 

Emerging Medications: The Case of GnRH Antagonist 

Recently developed products in a class of drugs known as GnRH (8) (Gonadotropin-Releasing Hormone) antagonists such as Relugolix (9) and Linzagolix (10) marks a revolutionary step in fibroid treatment. These medications work by reducing the production of estrogen and progesterone, hormones that can fuel fibroid growth and in turn symptoms, thereby offering a non-surgical option for managing fibroids. 

These medications have shown promising results in alleviating symptoms such as heavy menstrual bleeding and increasing the quality of life of patients living with fibroids. These treatments are available in differing formats to cater for different patient needs.  They can be found either in a combination therapy which contains the antagonist in combination with add-back therapy within the one tablet, or in a format where the antagonist can be taken alone or in combination with a separate add-back therapy. Add-back therapy (11), typically involves the co-administration of small doses of estrogen and progesterone, usually in the form of E2 and a progestin known as norethisterone acetate (NETA) which aims to balance the lowered hormone levels caused by the GnRH antagonists, mitigating potential side effects like bone density loss or menopausal symptoms. 

The addition of add-back therapy offers the patient an important balance between efficacy and safety. It allows patients to benefit from the symptom-relief properties offered by the GnRH antagonists while minimizing side effects associated with lowered hormone levels. This dual approach in turn enhances the quality of life for patients and offers a more tailored treatment strategy. 

Minimally Invasive Surgical Alternatives 

Techniques like Uterine Fibroid Embolization (UFE) (12) and laparoscopic myomectomy (13) have been significant additions to the surgical alternatives available for fibroid treatment. These minimally invasive procedures offer shorter recovery times, fewer complications, and are less traumatic compared to traditional surgery. They represent a significant improvement in patient care, offering effective treatment with must less disruption to a woman’s life. 

Future Directions in Fibroid Research 

Pioneering Cellular Models for Fibroid Study 

The use of advanced technologies such as CRISPR (14) for creating cellular models has opened other new avenues in fibroid research. These models help to understand the cellular mechanisms of fibroid growth, thus providing a foundation for developing targeted therapies. This type of ongoing research (15) is crucial for discovering potential new treatment options which could be more effective and have fewer side effects. 

Discovering Novel Pathways for Targeted Therapies 

Exploring specific biochemical pathways involved in fibroid development, such as the TDO2-kynurenine-AHR (16) pathway, also offers potential for novel treatments. Understanding these pathways will help in developing drugs which could specifically target these processes, offering a more personalized and effective treatment approach. 

The Shift Towards Personalized Fibroid Management 

The trend towards personalized fibroid management, (17) focusing on individual patient characteristics, genetics, and responses to treatment, is becoming increasingly prevalent. This personalized approach promises more effective and tailored treatment strategies, ensuring better patient outcomes. 

Envisioning a Future Without Fibroids 

This blog has summarized key advancements in fibroid research, emphasizing the potential impact on future management strategies. With continuous research, innovation, and collaboration in the medical community, we are moving closer to a future where fibroids can be effectively managed or even eradicated, improving the lives of millions of women worldwide. 

  1. George, J.W. The burden of uterine fibroids: an overview. Pages 153-155. Published online: 27 Nov 2023. 
  2. Buyukcelebi, K., Chen, X., Abdula, F., Elkafas, H., Duval, A.J., Ozturk, H., Seker-Polat, F., Jin, Q., Yin, P., Feng, Y., Bulun, S.E., Wei, J.J., Yue, F., Adli, M. 2023. Engineered MED12 mutations drive leiomyoma-like transcriptional and metabolic programs by altering the 3D genome compartmentalization. Nature Communications, 14, Article number: 4057. Published: 10 July 2023. [Open access]. 
  3. Lyons, M.J. 2021. MED12-Related Disorders. In GeneReviews® [Internet]. Initial Posting: June 23, 2008; Last Update: August 12, 2021. 
  4. Markowski, D.N., Bartnitzke, S., Löning, T., Drieschner, N., Helmke, B.M., Bullerdiek, J. 2012. MED12 mutations in uterine fibroids–their relationship to cytogenetic subgroups. International Journal of Cancer, 131(7): 1528-36. doi: 10.1002/ijc.27424. Epub 2012 Feb 28. PMID: 22223266. [Free article]. 
  5. Yang, Q., Ciebiera, M., Bariani, M.V., Ali, M., Elkafas, H., Boyer, T.G., Al-Hendy, A. 2022. Comprehensive Review of Uterine Fibroids: Developmental Origin, Pathogenesis, and Treatment. Endocrine Reviews, 43(4): 678-719. doi: 10.1210/endrev/bnab039. Published: Jul 13, 2022. PMID: 34741454. PMCID: PMC9277653. [Free PMC article]. 
  6. Automated Uterine Fibroids Detection in Ultrasound Images Using Deep Convolutional Neural Networks.” Healthcare (Basel), vol. 11, no. 10, 2023, p. 1493. Published online May 20, 2023. doi: 10.3390/healthcare11101493. PMCID: PMC10218188. PMID: 37239779 
  7. Theis, M., Tonguc, T., Savchenko, O., Nowak, S., Block, W., Recker, F., Essler, M., Mustea, A., Attenberger, U., Marinova, M., Sprinkart, A.M. 2023. Deep learning enables automated MRI-based estimation of uterine volume also in patients with uterine fibroids undergoing high-intensity focused ultrasound therapy. Insights Imaging, 14:1. Published online Jan 5, 2023. doi: 10.1186/s13244-022-01342-0. PMCID: PMC9813298. PMID: 36600120. 
  8. Di Spiezio Sardo, A., Ciccarone, F., Muzii, L., Scambia, G., Vignali, M. 2023. Use of oral GnRH antagonists combined therapy in the management of symptomatic uterine fibroids. Facts Views Vis Obgyn, 15(1): 29–33. Published online Mar 31, 2023. doi: 10.52054/FVVO.15.1.059. PMCID: PMC10392112. PMID: 37010332. 
  9. Baird, D.D., Harmon, Q.E. Relugolix — new treatment for uterine fibroid-related heavy bleeding. Nat Rev Endocrinol 17, 321–322 (2021). 
  10. Donnez, J., Taylor, H.S., Stewart, E.A., Bradley, L., Marsh, E., Archer, D., et al. 2022. Linzagolix with and without hormonal add-back therapy for the treatment of symptomatic uterine fibroids: two randomised, placebo-controlled, phase 3 trials. Published: September 17, 2022. DOI: 
  11. Wyatt, K.M., Dimmock, P.W., Ismail, K.M.K., Jones, P.W., O’Brien, P.M.S. The effectiveness of GnRHa with and without ‘add-back’ therapy in treating premenstrual syndrome: a meta analysis. PMID: 15198787. DOI: 10.1111/j.1471-0528.2004.00135.x. 
  12. Breakthrough in Understanding Genesis of Fibroids.” Science News from Research Organizations. University of Helsinki. Date: August 4, 2021. Summary: Scientists have made a breakthrough in understanding the genesis of uterine leiomyomas, also called fibroids. 
  13. Dumitrașcu, M.C., Nenciu, C.-G., Nenciu, A.-E., Călinoiu, A., Neacșu, A., Cîrstoiu, M., Șandru, F. 2023. Laparoscopic myomectomy – The importance of surgical techniques. Frontiers in Medicine (Lausanne), 10: 1158264. Published online Mar 20, 2023. doi: 10.3389/fmed.2023.1158264. PMCID: PMC10067888. PMID: 37020679. Note: This article has been corrected. See Front Med (Lausanne). 2023 Aug 21; 10: 1251421. 
  14. Liu, W., Li, L., Jiang, J., Wu, M., Lin, P. 2021. Applications and challenges of CRISPR-Cas gene-editing to disease treatment in clinics. Precis Clin Med, 4(3): 179–191. Published online Jul 10, 2021. doi: 10.1093/pcmedi/pbab014. PMCID: PMC8444435. PMID: 34541453. 
  15. Machado-Lopez, A., Simón, C., Mas, A. 2021. Molecular and Cellular Insights into the Development of Uterine Fibroids. International Journal of Molecular Sciences, 22(16): 8483. Published online Aug 6, 2021. doi: 10.3390/ijms22168483. PMCID: PMC8395213. PMID: 34445194. Academic Editor: Gyozo Garab. 
  16. “Study Identifies Novel Cellular Mechanisms Promoting Growth of Uterine Fibroids.” Editors’ Notes. By Melissa Rohman, Northwestern University. September 20, 2023. 
  17. El Sabeh, M., Borahay, M.A. 2021. The Future of Uterine Fibroid Management: a More Preventive and Personalized Paradigm. Reproductive Sciences, 28(11): 3285-3288. doi: 10.1007/s43032-021-00618-y. Epub 2021 May 18. PMID: 34008153. PMCID: PMC9228730. [Free PMC article]. 
Other topics you might be interested in See All
Other topics See All